PIPC submitted a comment letter to the Washington Prescription Drug Affordability Board (PDAB) highlighting the concerns of patients and people with disabilities related to the PDAB’s potential use of discriminatory cost effectiveness analyses.
The letter calls on the Washington PDAB to reject the use of studies relying on one-size-fits-all metrics like the quality-adjusted-life-years (QALYs) and the equal value of life years gained (evLYG). PIPC is very very concerned that entities including the Program on Regulation, Therapeutics, and Law (PORTAL) and the Institute for Clinical and Economic Review (ICER) publicly view the QALY as the gold standard for measuring cost effectiveness, a fact that will undermine the trust of patients and people with disabilities if they continue to be consulted in the PDAB’s work.
"Across other states, PDABs have struggled and too often failed to meaningfully incorporate patient perspectives or respond to their questions and concerns," wrote PIPC Chair Tony Coelho. "We are hopeful Washington State’s PDAB will do better."
"Across other states, PDABs have struggled and too often failed to meaningfully incorporate patient perspectives or respond to their questions and concerns," wrote PIPC Chair Tony Coelho. "We are hopeful Washington State’s PDAB will do better."
| pipc_washington_pdab_2024.pdf |
